These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 9829492)

  • 1. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
    Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
    Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
    Lin CL; Hsu PY; Yang HY; Huang CC
    Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC; Huang TP; Chen TW; Yang WC
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients.
    Sezer S; Ozdemir FN; Yakupoglu U; Arat Z; Turan M; Haberal M
    Artif Organs; 2002 Apr; 26(4):366-70. PubMed ID: 11952508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients.
    Chuang CL; Liu RS; Wei YH; Huang TP; Tarng DC
    Nephrol Dial Transplant; 2003 Feb; 18(2):370-7. PubMed ID: 12543894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration.
    Gastaldello K; Vereerstraeten A; Nzame-Nze T; Vanherweghem JL; Tielemans C
    Nephrol Dial Transplant; 1995; 10 Suppl 6():44-7. PubMed ID: 8524494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients.
    Chan D; Irish A; Dogra G
    Nephrology (Carlton); 2005 Aug; 10(4):336-40. PubMed ID: 16109077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients.
    Taji Y; Morimoto T; Okada K; Fukuhara S; Fukui T; Kuwahara T
    J Nephrol; 2004; 17(4):537-43. PubMed ID: 15372416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE; Peat N; Porter C; Morgan AG
    Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of ascorbic acid in suboptimal responsive anemic hemodialysis patients receiving erythropoietin: a meta-analysis.
    Einerson B; Chaiyakunapruk N; Kitiyakara C; Maphanta S; Thamlikitkul V
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S134-46. PubMed ID: 21721439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
    Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
    Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients.
    Tarng DC; Hung SC; Huang TP
    J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients.
    Goicoechea M; Vazquez MI; Ruiz MA; Gomez-Campdera F; Perez-García R; Valderrábano F
    Nephron; 1998; 78(1):23-7. PubMed ID: 9453399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
    De Marchi S; Cecchin E
    Clin Sci (Lond); 1991 Jul; 81(1):113-21. PubMed ID: 1649718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin and iron: the role of ascorbic acid.
    Tarng DC; Huang TP; Wei YH
    Nephrol Dial Transplant; 2001; 16 Suppl 5():35-9. PubMed ID: 11509682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
    Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
    J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.